Chemistry and life science innovations often require extended research and development before generating revenue. VC funding provides the patient, high-risk capital necessary to support these lengthy product life cycles—often referred to as the “valley of death” between initial lab discovery and commercial products
Venture capitalists invest in quantum computing primarily for its potential to revolutionize chemical engineering and the life sciences by accurately simulating molecular structures.
IQT Quantum Chemistry and Life Sciences next provides an alphabetical listing below of Venture Capital firms investing in these two sectors. This is not a comprehensive list, but active VCs and strategic funds on record as backing these intersections.
Quantum Chemistry Funds
Quantum Chemistry Investors
- Accelerator Funds: Early-stage deep-tech funds such as Rockstart have backed quantum chemistry startups (like Molecular Quantum Solutions) that provide software platforms for calculating thermodynamic properties
- DCVC (Data Collective): Focuses heavily on deep tech, climate tech, and quantum computing infrastructure designed to accelerate scientific breakthroughs.
- Khosla Ventures: Deep tech and computational science firm focused on quantum-enabled materials discovery.
- Lux Capital: Backs frontier tech, advanced hardware, and next-generation computational chemistry platforms.
- Novo Holdings Quantum: (the investment arm of the Novo Nordisk Foundation) invests directly in quantum software startups that address life sciences and chemical simulations.
- Quantonation: A dedicated early-stage fund focused on quantum computing, deep physics, and companies bridging the gap between laboratories and practical quantum chemistry applications.
Publications and investment groups tracking or leading the quantum-chemistry venture space include:
- McKinsey & Company: Analyzes how high-precision quantum molecular simulations will speed up novel material design, advanced formulations, and high-performance catalysts. [1]
- Fierce Biotech: Explores the entrance of Big Pharma and dedicated holding firms into the quantum realm for protein/peptide design and biomarker discovery.
- VC Cafe: Offers an industry overview of quantum funding momentum, mega-rounds, and the shift toward practical applications.
- Yale Quantum Institute: Tracks the global movement of private capital and the transition of academic quantum chemistry research into commercial start-ups.
**********************************************************************************
Quantum Life Science Funds
VCs at the intersection of quantum computing and life sciences specialize in highly technical deep tech. They target startups solving lengthy, complex R&D problems—such as using quantum-assisted simulations to drastically accelerate drug discovery, molecular design, and protein folding.The following specialized firms and funds are actively writing checks for startups bridging these two disciplines:
Quantum-Life Science Investors
- Intel Capital: Actively looks at the quantum software and application layers, specifically targeting the convergence of AI and quantum for the pharmaceutical industry.
- Qai Ventures: Backs advanced computing across the value chain, actively deploying both a $50M Early-Stage Fund and a $150M Growth-Stage Fund for verticals that include life sciences and deep physics.
- Quantonation: Operating as a massive physics and deep-tech fund (over €220M in Fund II), they invest heavily in companies building quantum algorithms, sensing, and tech capable of pharmaceutical breakthroughs
- Novo Holdings Quantum: Part of the massive Novo Nordisk ecosystem, they are a primary driver of direct investments into quantum software designed for healthcare and medicinal applications.
Deep Tech & Healthcare Specialists investing in quantum and life sciences:
- IQ Capital: A deep-tech fund managing $1B+ that regularly evaluates early-stage quantum, AI, and life science platforms requiring long-term, specialized funding.
- Cambridge Innovation Capital: Invests in both deep tech (like quantum and AI) and life sciences (including therapeutics and genomics) while connecting founders directly to their sprawling corporate network.
- DCVC Bio: A prominent firm that sits at the exact intersection of data, biology, and computational breakthroughs, funding tech-heavy approaches to modern medicine.